Geode Capital Management’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$44.4M Buy
3,172,305
+135,129
+4% +$1.89M ﹤0.01% 1492
2025
Q1
$41.3M Buy
3,037,176
+101,893
+3% +$1.39M ﹤0.01% 1495
2024
Q4
$59.8M Sell
2,935,283
-20,194
-0.7% -$412K ﹤0.01% 1318
2024
Q3
$86.1M Sell
2,955,477
-27,061
-0.9% -$788K 0.01% 1083
2024
Q2
$69.3M Buy
2,982,538
+222,905
+8% +$5.18M 0.01% 1146
2024
Q1
$56.6M Buy
2,759,633
+100,337
+4% +$2.06M 0.01% 1268
2023
Q4
$57.1M Buy
2,659,296
+127,461
+5% +$2.74M 0.01% 1260
2023
Q3
$52.2M Buy
2,531,835
+213,538
+9% +$4.41M 0.01% 1211
2023
Q2
$68.4M Buy
2,318,297
+172,125
+8% +$5.08M 0.01% 1023
2023
Q1
$49.4M Buy
2,146,172
+96,215
+5% +$2.22M 0.01% 1201
2022
Q4
$57M Buy
2,049,957
+273,793
+15% +$7.61M 0.01% 1066
2022
Q3
$54.5M Buy
1,776,164
+69,583
+4% +$2.14M 0.01% 1020
2022
Q2
$50.2M Buy
1,706,581
+75,634
+5% +$2.23M 0.01% 1116
2022
Q1
$52.5M Buy
1,630,947
+2,080
+0.1% +$66.9K 0.01% 1223
2021
Q4
$72.6M Buy
1,628,867
+21,473
+1% +$958K 0.01% 1017
2021
Q3
$81.1M Buy
1,607,394
+90,373
+6% +$4.56M 0.01% 926
2021
Q2
$119M Buy
1,517,021
+264,189
+21% +$20.7M 0.02% 707
2021
Q1
$71.5M Buy
1,252,832
+97,930
+8% +$5.59M 0.01% 953
2020
Q4
$96.7M Buy
1,154,902
+68,773
+6% +$5.76M 0.02% 714
2020
Q3
$38.9M Buy
1,086,129
+5,179
+0.5% +$186K 0.01% 1060
2020
Q2
$26.1M Buy
1,080,950
+98,431
+10% +$2.38M 0.01% 1301
2020
Q1
$17.2M Buy
982,519
+114,901
+13% +$2.01M ﹤0.01% 1405
2019
Q4
$15.1M Buy
867,618
+24,847
+3% +$433K ﹤0.01% 1735
2019
Q3
$12.9M Buy
842,771
+19,138
+2% +$293K ﹤0.01% 1756
2019
Q2
$17.1M Buy
823,633
+49,746
+6% +$1.03M ﹤0.01% 1589
2019
Q1
$18M Buy
773,887
+63,865
+9% +$1.48M ﹤0.01% 1487
2018
Q4
$14.7M Buy
710,022
+677
+0.1% +$14K ﹤0.01% 1500
2018
Q3
$15.4M Buy
709,345
+503,195
+244% +$10.9M ﹤0.01% 1600
2018
Q2
$3.14M Buy
206,150
+58,072
+39% +$885K ﹤0.01% 2591
2018
Q1
$2.92M Buy
+148,078
New +$2.92M ﹤0.01% 2556